PUBLISHER: Daedal Research | PRODUCT CODE: 1341010
PUBLISHER: Daedal Research | PRODUCT CODE: 1341010
Global Respiratory Syncytial Virus (RSV) Vaccine And Antibody Pipeline Market: Analysis By End User (Adult and Maternal & Pediatric), By Type (Vaccine & Antibody), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030
RSV, or respiratory syncytial virus, is a common respiratory virus that causes mild, cold-like symptoms in both the upper and lower respiratory tracts. RSV can be harmful, especially in infants and the elderly, even though most individuals recover in a week or two. According to the Cleveland Clinic, RSV affects around 57,000 children under the age of five in the US each year. Despite massive global research efforts and decades of targeting RSV, there is still a significant unmet medical need. Potential therapeutics have had a difficult time proving a favorable safety profile or efficacy in the past. However, the RSV vaccine development has made significant progress during the last ten years. The RSV vaccine and antibody market is expected to grow at a CAGR of 31.65% during the years 2024-2030.
After almost six decades of striving, the effective vaccination against the life-threatening respiratory syncytial virus (RSV) has been achieved. The FDA has granted approval for two new RSV vaccines in H1 2023: GSK's Arexvy, and Pfizer's Abrysvo. These vaccines specifically target adults aged 60 and above, a group highly susceptible to this infection. The commercialization and accessibilty of these is expected by 2024. The estimates are done for the period, 2024 to 2030. Considering both the modalities (antibody and vaccine) targeting all three key age groups, the global RSV vaccine and antibody market is expected to be worth US$2.61 billion in 2024, rising to US$13.59 billion by 2030.
Market Segmentation Analysis:
By Type: The report provides the bifurcation of respiratory syncytial virus vaccine and antibody market into two segments on the basis of type: Vaccine and Antibody. In 2024, the vaccine segment is foreseen to lead the respiratory syncytial virus vaccine and antibody market. RSV vaccines are now being tested in numerous clinical trials. Sanofi, GlaxoSmithKline, Pfizer, and Moderna, are among the companies engaging in vaccination production. Targeting the pre fusion conformation of the F protein is a frequent trend in the last generation of RSV vaccines. The growth of the segment is expected to be driven by increased government funding for vaccine development, increased investments by major players, rising RSV prevalence, technical improvements, and activities by NGOs.
By End User: The report identifies two segments on the basis of end user: Adult, and Maternal And Pediatric. The adult segment is likely to dominate the respiratory syncytial virus vaccine and antibody market in 2024. The rising incidence of RSV in older and immunocompromised adults has gained a lot of traction over the years, and several major players have begun adult vaccine and antibody trials, which is seen as a key factor in giving the adult segment a dominant share.
By Region: In the report, the global respiratory syncytial virus vaccine and antibody market is divided into three regions: The US, Europe, and ROW. The US is projected to dominate the market in 2024 by occupying almost half of the share of the global market. The most important factor driving the respiratory syncytial virus vaccine and antibody market in the US is rising prevalence of RSV. Moreover, presence of major players and good healthcare facilities in the region would boost the US respiratory syncytial virus vaccine and antibody market in the years to come. Europe respiratory syncytial virus vaccine and antibody market provides lucrative opportunities in the coming years. Various reasons such as improved healthcare infrastructure, changing demographic divion, an active government drive to track RSV seasons, and a well-established reimbursement system for hospitals, are expected to drive the growth of the market in Europe
Global Respiratory Syncytial Virus Vaccine And Antibody Market Dynamics:
Growth Drivers: The global respiratory syncytial virus vaccine and antibody market is likely to be driven by the rising prevalence of respiratory syncytial virus highlighting the greater unmet need for RSV vaccines. RSV is extremely contagious. The incubation phase might last anywhere between two and eight days. Close contact with infected people via respiratory droplets or contact with contaminated surfaces or items spreads the virus from respiratory secretions. RSV affects roughly 57,000 children under the age of five in the US each year, according to data provided by the Cleveland Clinic. RSV also causes about 177,000 adult hospitalizations each year. Furthermore, the factors such as rapid urbanization, increasing geriatric population, increase in healthcare expenditure, growing instances of RSV among kids, and favorable government support have constantly supported the development of vaccines and antibodies in the past years, propelling the growth of the market.
Challenges: Some challenges are also impeding the growth of the market such as high cost of vaccine development and inequitable access to vaccines. Pharmaceutical companies have had substantial difficulties in developing medications to treat RSV, as seen by the approval of only one product, Synagis, in the last two decades. In the late stages of development, a huge number of monoclonal antibody and vaccine candidates have failed to attain the needed efficacy and have suffered serious setbacks.
Trends: The market is projected to grow at a fast pace during the forecast period, due to various latest trends such as use of artificial intelligence (AI) in vaccine and drug design, technological advancements in vaccine administration and competitive pipeline. The use of monoclonal antibodies in neonates to enhance passive immunization is one of the key techniques being researched by pharmaceuticals in their fight against RSV. The pipeline products outperform Synagis and the other technique of vaccination pregnant mothers to provide infants with passive immunization.
Impact Analysis of COVID-19 and Way Forward:
RSV epidemiology has changed substantially as a result of the COVID-19 pandemic. In fact, the RSV season in 2020 was short or non-existent in many areas, with only a few cases. Trial recruitment had largely paused while numerous immunization protocols for COVID-19 were being developed. The RSV season in the US is usually assumed to begin in October and peak between late December and mid-February, however this has altered to a later date. The CDC has noticed that a recent rise in RSV cases, which is generally rarely seen in the summer, has drastically altered the RSV research environment. While the COVID-19 pandemic pushed vaccine development to the forefront, it also slowed clinical research in several therapeutic areas, such as respiratory syncytial virus (RSV).
The post-COVID-19 scenario for the RSV vaccine and antibody market is very promising. The pandemic has raised awareness of the need for RSV prevention, and the recent approval of two adult RSV vaccines, GSK's Arexvy and Pfizer's Abrysvo, is expected to further boost demand for RSV vaccines. Arexvy is the first RSV vaccine to be approved in the US, and it is indicated for the prevention of lower respiratory tract disease caused by RSV in adults 65 years of age and older. Abrysvo is also indicated for the prevention of lower respiratory tract disease caused by RSV in adults 60 years of age and older. In addition to Arexvy and Abrysvo, there are several other RSV vaccines and antibodies in development.
Competitive Landscape:
The global Respiratory syncytial virus vaccine and antibody market is concentrated. RSV (respiratory syncytial virus) has long been a vaccine target. Vaccines are finally making their way through late-stage testing, despite a number of high-profile trial failures over the years. Key players are focusing on inorganic growth by conducting RSV vaccine clinical trials in order to increase their market share and presence, as well as expanding their capabilities with broader offers to meet growing market demand. RSV vaccines developed by Pfizer and GlaxoSmithKline have been recently approved by FDA. Sanofi and AstraZeneca, as a partner are adopting a different tack by developing a preventive monoclonal antibody for infants. Collaborations and partnerships, innovative product releases, and expansions of manufacturing and distribution units are some of the primary strategies used by companies in global respiratory syncytial virus vaccine and antibody market.
The key players of the global respiratory syncytial virus vaccine and antibody market are
Pfizer Inc.
GlaxoSmithKline
AstraZeneca Plc.
Merck & Co. Inc.
Sanofi
Moderna Inc.
Meissa Vaccines
Advaccine
Codagenix
The players of the market are focusing on inorganic growth by conducting RSV vaccine clinical trials in order to increase their market share and presence, as well as expanding their capabilities with broader offers to meet growing market demand. Collaborations and partnerships, innovative product releases, and expansions of manufacturing and distribution units are some of the primary strategies used by companies in global respiratory syncytial virus vaccine and antibody market.
Table of Contents
- 2.1 Respiratory Syncytial Virus (RSV) Vaccine & Antibody: An Overview
- 2.1.1 Antigenic Subtypes Of Respiratory Syncytial Virus
- 2.1.2 What went wrong with previous RSV vaccines?
- 2.1.3 Pre F Protein & It's Increasing Use in RSV Vaccines
- 2.2 RSV Vaccine & Antibody (RSV) Segmentation: An Overview
- 2.2.1 Respiratory Syncytial Virus Vaccine & Antibody Segmentation
- 3.1 Global RSV Vaccine And Antibody Market: An Analysis
- 3.1.1 Global RSV Vaccine And Antibody Market: An Overview
- 3.1.2 Global RSV Vaccine And Antibody Market by Value
- 3.1.3 Global RSV Vaccine And Antibody Market by End User (Adult and Maternal & Pediatric)
- 3.1.4 Global RSV Vaccine And Antibody Market by Type (Vaccine and Antibody)
- 3.1.5 Global RSV Vaccine And Antibody Market by Region (The US, Europe and ROW)
- 3.2 Global RSV Vaccine And Antibody Market: End User Analysis
- 3.2.1 Global RSV Vaccine And Antibody Market by End User: An Overview
- 3.2.2 Global Adult RSV Vaccine And Antibody Market by Value
- 3.2.3 Global Maternal & Pediatric RSV Vaccine And Antibody Market by Value
- 3.3 Global RSV Vaccine And Antibody Market: Type Analysis
- 3.3.1 Global RSV Vaccine And Antibody Market by Type: An Overview
- 3.3.2 Global RSV Vaccine Market by Value
- 3.3.3 Global RSV Vaccine Market by End User (Adult and Maternal & Pediatric)
- 3.3.4 Global RSV Vaccine Market by Region (The US, Europe and ROW)
- 3.3.5 Global RSV Antibody Market by Value
- 3.3.6 Global RSV Antibody Market by Region
- 3.4 Global RSV Vaccine Market: End User Analysis
- 3.4.1 Global RSV Vaccine Market by End User: An Overview
- 3.4.2 Global Adult RSV Vaccine Market by Value
- 3.4.3 Global Maternal & Pediatric RSV Vaccine Market by Value
- 4.1 The US RSV Vaccine And Antibody Market: An Analysis
- 4.1.1 The US RSV Vaccine And Antibody Market: An Overview
- 4.1.2 The US RSV Vaccine And Antibody Market by Value
- 4.1.3 The US RSV Vaccine Market by Value
- 4.1.4 The US RSV Vaccine Market by End User (Adult and Maternal & Pediatric)
- 4.1.5 The US Adult RSV Vaccine Market by Value
- 4.1.6 The US Adult RSV Vaccine Market Product Type by Value
- 4.1.7 The US Maternal & Pediatric RSV Vaccine Market by Value
- 4.1.8 The US Maternal & Pediatric RSV Vaccine Market Product Type by Value
- 4.1.9 The US RSV Antibody Market by Value
- 4.1.10 The US RSV Antibody Market Product Type by Value
- 4.2 Europe RSV Vaccine And Antibody Market: An Analysis
- 4.2.1 Europe RSV Vaccine And Antibody Market: An Overview
- 4.2.2 Europe RSV Vaccine And Antibody Market by Value
- 4.2.3 Europe RSV Vaccine Market by Value
- 4.2.4 Europe RSV Vaccine Market by End User (Adult and Maternal & Pediatric)
- 4.2.5 Europe Adult RSV Vaccine Market by Value
- 4.2.6 Europe Adult RSV Vaccine Market Product Type by Value
- 4.2.7 Europe Maternal & Pediatric RSV Vaccine Market by Value
- 4.2.8 Europe Maternal & Pediatric RSV Vaccine Market Product Type by Value
- 4.2.9 Europe RSV Antibody Market by Value
- 4.2.10 Europe RSV Antibody Market Product Type by Value
- 4.3 ROW RSV Vaccine And Antibody Market: An Analysis
- 4.3.1 ROW RSV Vaccine And Antibody Market: An Overview
- 4.3.2 ROW RSV Vaccine And Antibody Market by Value
- 4.3.3 ROW RSV Vaccine Market by Value
- 4.3.4 ROW RSV Vaccine Market by End User (Adult and Maternal & Pediatric)
- 4.3.5 ROW Adult RSV Vaccine Market by Value
- 4.3.6 ROW Adult RSV Vaccine Market Product Type by Value
- 4.3.7 ROW Maternal & Pediatric RSV Vaccine Market by Value
- 4.3.8 ROW Maternal & Pediatric RSV Vaccine Market Product Type by Value
- 4.3.9 ROW RSV Antibody Market by Value
- 4.3.10 ROW RSV Antibody Market Product Type by Value
- 5.1 Impact of COVID-19
- 5.1.1 Impact of COVID-19 on Healthcare
- 5.1.2 Impact of COVID-19 Restrictions on RSV Transmission
- 5.1.3 Post COVID Scenario
- 6.1 Growth Drivers
- 6.1.1 Rapid Urbanization
- 6.1.2 Aging Population
- 6.1.3 Increasing Healthcare Expenditure
- 6.1.4 Rising Prevalence of Respiratory Syncytial Virus
- 6.1.5 Greater Unmet Need
- 6.1.6 Growing Instances of RSV Among Infants
- 6.1.7 Favorable Government Support
- 6.2 Challenges
- 6.2.1 High Cost of Vaccine Development
- 6.2.2 Inequitable Access to Vaccines
- 6.3 Market Trends
- 6.3.1 Use of Artificial Intelligence (AI) in Vaccine and Drug Design
- 6.3.2 Technological Advancements in Vaccine Administration
- 6.3.3 Competitive Pipeline
- 7.1 Global RSV Vaccine And Antibody Market: Vaccine & Antibody Candidates
- 7.2 Global RSV Vaccine And Antibody Players By Market Share
- 7.3 Global RSV Vaccine And Antibody Market: Current Landscape
- 8.1 GlaxoSmithKline Plc
- 8.1.1 Business Overview
- 8.1.2 Sales by Products
- 8.1.3 Business Strategies
- 8.2 Merck & Co., Inc.
- 8.2.1 Business Overview
- 8.2.2 Operating Segments
- 8.2.3 Business Strategies
- 8.3 Pfizer Inc.
- 8.3.1 Business Overview
- 8.3.2 Operating Segments
- 8.3.3 Business Strategies
- 8.4 AstraZeneca Plc
- 8.4.1 Business Overview
- 8.4.2 Operating Segments
- 8.4.3 Business Strategies
- 8.5 Sanofi S.A.
- 8.5.1 Business Overview
- 8.5.2 Operating Segments
- 8.5.3 Business Strategy
- 8.6 Moderna Inc.
- 8.6.1 Business Overview
- 8.6.2 Operating Regions
- 8.6.3 Business Strategies
- 8.7 Meissa Vaccines
- 8.7.1 Business Overview
- 8.7.2 Business Strategies
- 8.8 Codagenix
- 8.8.1 Business Overview
- 8.8.2 Business Strategies
- 8.9 Advaccine
- 8.9.1 Business Overview
1. Executive Summary
2. Introduction
3. Global Market Analysis
4. Regional Market Analysis
5. Impact of COVID-19
6. Market Dynamics
7. Competitive Landscape
8. Company Profiles
List of Tables
- Table 1: RSV V/S COVID-19
- Table 2: Global RSV Vaccine And Antibody Snapshot
Table 3 : Global RSV Vaccine And Antibody Players By Market Share; 2024-2030 (Percentage, %)
- Table 4: Global RSV Vaccine And Antibody Market: Current Landscape
List of Figures
- Figure 1: Antigenic Subtypes Of Respiratory Syncytial Virus
- Figure 2: What went wrong with previous RSV vaccines?
- Figure 3: Pre F Protein & It's Increasing Use in RSV Vaccines
- Figure 4: Respiratory Syncytial Virus Vaccine & Antibody Segmentation
- Figure 5: Global RSV Vaccine And Antibody Market by Value; 2024-2030 (US$ Billion)
- Figure 6: Global RSV Vaccine And Antibody Market by End User; 2024 (Percentage, %)
- Figure 7: Global RSV Vaccine And Antibody Market by Type; 2024 (Percentage, %)
- Figure 8: Global RSV Vaccine And Antibody Market by Region; 2024 (Percentage, %)
- Figure 9: Global Adult RSV Vaccine And Antibody Market by Value; 2024-2030 (US$ Billion)
- Figure 10: Global Maternal & Pediatric RSV Vaccine And Antibody Market by Value; 2024-2030 (US$ Billion)
- Figure 11: Global RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
- Figure 12: Global RSV Vaccine Market by End User; 2024 (Percentage, %)
- Figure 13: Global RSV Vaccine Market by Region; 2024 (Percentage, %)
- Figure 14: Global RSV Antibody Market by Value; 2024-2030 (US$ Billion)
- Figure 15: Global RSV Antibody Market by Region; 2024 (Percentage, %)
- Figure 16: Global Adult RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
- Figure 17: Global Maternal & Pediatric RSV Vaccine Market by Value; 2024-2030 (US$ Million)
- Figure 18: The US RSV Vaccine And Antibody Market by Value; 2024-2030 (US$ Billion)
- Figure 19: The US RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
- Figure 20: The US RSV Vaccine Market by End User; 2024 (Percentage, %)
- Figure 21: The US Adult RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
- Figure 22: The US Adult RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
- Figure 23: The US Maternal & Pediatric RSV Vaccine Market by Value; 2024-2030 (US$ Million)
- Figure 24: The US Maternal & Pediatric RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
- Figure 25: The US RSV Antibody Market by Value; 2024-2030 (US$ Million)
- Figure 26: The US RSV Antibody Market Product Type by Value; 2024-2030 (US$ Million)
- Figure 27: Europe RSV Vaccine And Antibody Market by Value; 2024-2030 (US$ Billion)
- Figure 28: Europe RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
- Figure 29: Europe RSV Vaccine Market by End User; 2024 (Percentage, %)
- Figure 30: Europe Adult RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
- Figure 31: Europe Adult RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
- Figure 32: Europe Maternal & Pediatric RSV Vaccine Market by Value; 2024-2030 (US$ Million)
- Figure 33: Europe Maternal & Pediatric RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
- Figure 34: Europe RSV Antibody Market by Value; 2024-2030 (US$ Million)
- Figure 35: Europe RSV Antibody Market Product Type by Value; 2024-2030 (US$ Million)
- Figure 36: ROW RSV Vaccine And Market by Value; 2024-2030 (US$ Billion)
- Figure 37: ROW RSV Vaccine Market by Value; 2024-2030 (US$ Billion)
- Figure 38: ROW RSV Vaccine Market by End User; 2024 (Percentage, %)
- Figure 39: ROW Adult RSV Vaccine Market by Value; 2024-2030 (US$ Million)
- Figure 40: ROW Adult RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
- Figure 41: ROW Maternal & Pediatric RSV Vaccine Market by Value; 2024-2030 (US$ Million
- Figure 42: ROW Maternal & Pediatric RSV Vaccine Market Product Type by Value; 2024-2030 (US$ Million)
- Figure 43: ROW RSV Antibody Market by Value; 2024-2030 (US$ Million)
- Figure 44: ROW RSV Antibody Market Product Type by Value; 2024-2030 (US$ Million)
- Figure 45: Global Urban Population as a Share of Total Population; 2016, 2021 & 2050 (Percentage, %)
- Figure 46: Global Percentage Of Population Aged 65 Years Or Over; 2022, 2030 & 2050 (Percentage, %)
- Figure 47: The US Health Consumption Expenditure as a Percentage of GDP; 2016-2022 (Percentage, %)
- Figure 48: Global Market Size for Artificial Intelligence in Healthcare; 2021-2030 (US $Billion)
- Figure 49: GlaxoSmithKline Plc Sales by Products; 2022 (Percentage, %)
- Figure 50: Merck & Co., Inc. Sales by Segments; 2022 (Percentage, %)
- Figure 51: Pfizer Inc. Revenue by Segment; 2022 (Percentage,%)
- Figure 52: AstraZeneca Total Revenue by Disease Areas; 2022 (Percentage, %)
- Figure 53: Sanofi S.A. Net Sales by Segments; 2022 (Percentage,%)
- Figure 54: Moderna Inc. Total Revenue by Geographic Area; 2022 (Percentage,%)
